Cell transplantation causes loss of gap junctions and activates GGT expression permanently in host liver

Sanjeev Gupta1,2,3, Pankaj Rajvanshi2,3, Harmeet Malhi2,3, Sanjeev Slehria2,3, Rana P. Sokhi2,3, Srinivasa R. G. Vasa2,3, Mariana D. Dabeva2,3, David A. Shafritz4,1,2,3,5, Andrew Kerr6
1Comprehensive Cancer Research Center, and Departments of
2Marion Bessin Liver Research Center
3Medicine
4Cell Biology,
5Pathology, and
6Radiology, Albert Einstein College of Medicine, Bronx, New York 10461

Tóm tắt

Cell transplantation into hepatic sinusoids, which is necessary for liver repopulation, could cause hepatic ischemia. To examine the effects of cell transplantation on host hepatocytes, we transplanted Fisher 344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient rats. Within 24 h of cell transplantation, areas of ischemic necrosis, along with transient disruption of gap junctions, appeared in the liver. Moreover, host hepatocytes expressed γ-glutamyl transpeptidase (GGT) extensively, which was observed even 2 years after cell transplantation. GGT expression was not associated with α-fetoprotein activation, which is present in progenitor cells. Increased GGT expression was apparent after transplantation of nonparenchymal cells and latex beads but not after injection of saline, fragmented hepatocytes, hepatocyte growth factor, or turpentine. Some host hepatocytes exhibited apoptosis, as well as DNA synthesis, between 24 and 48 h after cell transplantation. Changes in gap junctions, GGT expression, DNA synthesis, and apoptosis after cell transplantation were prevented by vasodilators. The findings indicated the onset of ischemic liver injury after cell transplantation. These hepatic perturbations must be considered when transplanted cells are utilized as reporters for biological studies.

Từ khóa


Tài liệu tham khảo

Beer DG, 1996, Cancer Res, 46, 2435

10.1084/jem.170.1.349

Bone SN, 1985, Cancer Res, 45, 1222

Brouillet A, 1994, J Biol Chem, 269, 14878, 10.1016/S0021-9258(17)36547-X

10.1126/science.274.5291.1379

Dabeva M, 1993, Am J Pathol, 143, 1606

10.1073/pnas.94.14.7356

10.1055/s-2007-979944

10.1093/carcin/8.12.1837

10.1016/S0304-3835(98)00388-7

10.1083/jcb.119.3.493

10.1002/(SICI)1097-4652(199704)171:1<20::AID-JCP3>3.0.CO;2-J

10.3109/10408368009108725

Greenwel P, 1995, Lab Invest, 72, 83

10.1002/hep.1840140124

10.1016/S0168-8278(99)80022-1

10.1152/ajpgi.1999.276.3.G629

10.1002/(SICI)1096-9896(200002)190:2<203::AID-PATH521>3.0.CO;2-2

10.1073/pnas.92.13.5860

10.1002/hep.510290213

10.1089/hum.1994.5.8-959

10.1002/mc.2940050112

10.1016/S0002-9440(10)65574-5

10.1002/hep.510240126

10.1007/BF00495663

Miller SB, 1982, J Natl Cancer Inst, 68, 851

10.1152/ajpcell.1997.272.4.C1286

10.1002/(SICI)1096-9896(199902)187:3<365::AID-PATH237>3.0.CO;2-Z

10.1038/ng0396-266

10.1002/hep.510270218

10.1002/(SICI)1098-2744(199806)22:2<120::AID-MC7>3.0.CO;2-Q

10.1016/S0016-5085(96)70078-1

10.1002/hep.510230313

10.1006/excr.1998.4223

10.1126/science.8108734

10.1177/17.8.517

10.1159/000469243

10.1007/BF00964539

10.1093/carcin/11.1.69

10.1002/jcp.1041260204

10.1093/carcin/16.1.101

10.1016/0378-4274(95)03587-7

10.1136/bmj.1.5849.316

10.1007/BF02620872

10.1016/0270-9139(95)94569-5

10.1016/S0940-2993(11)80010-2

10.1006/excr.1994.1170